Proactive Investors - Run By Investors For Investors

Aphria forms special committee to review its Latin American acquisitions

A report from the short-seller Quintessential Capital Management calls Aphria a 'black hole' and takes aim at the company's recent C$280 million worth of Latin American acquisitions
cannabis plant
Quintessential Capital Management refers to Aphria's Latin American acquisitions as 'largely worthless'

The board of Canadian cannabis company Aphria Inc (TSX:APHA) (NYSE:APHA) has appointed a special committee of independent directors to review its takeover of LATAM Holdings in a bid to address “inaccurate and misleading” accusations by short-sellers.

The move comes after shares of Aphria tumbled this week in response to a report by the short-seller Quintessential Capital Management, which calls Aphria a “black hole” and takes aim at Aphria’s recent C$280 million worth of Latin American acquisitions.

In Thursday's morning trading session, Aphria shares kept sliding, falling by another 13.5% to $3.90.

READ: Canadian medical marijuana company Aphria pegs C$225mln war chest to build new facilities

Released on Monday, the report by Quintessential Capital Management and Hindenburg Research says Aphria’s Latin American acquisitions “raise major red flags” and that the transactions appear to be largely worthless based on extensive "on-the-ground" research.

The Quintessential analysts went so far as to accuse Aphria of being "a shell game with a cannabis business on the side". 

"We are of the strong opinion that Aphria is part of a scheme orchestrated by a network of insiders to divert funds away from shareholders into their own pockets," the analysts wrote.

On Thursday, Aphria again backed its Latin American operations and strategy and reiterated its confidence in the process leading to its acquisitions there.

But in the face of the criticism by the short sellers, Aphria is undertaking a comprehensive review, led by John Herhalt, Shlomo Bibas and Tom Looney. Herhalt, the lead independent director and chair of the audit committee, will chair the committee.

“We are committed to protecting our shareholders and restoring market confidence by confirming all the facts through an independent process to rebut innuendo and deception,” said Vic Neufeld, Aphria’s CEO in a statement.

Contact Ellen Kelleher at [email protected]

 

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full APH profile View Profile

Aphria Timeline

Related Articles

medical cannabis
October 01 2018
The companies will collaborate on activities to develop cannabinoid medicines as a medical option in Chile.
Cannabis leaf
November 19 2018
With the legalisation of recreational cannabis in Canada in October, and the US expected to follow suit, the company has its sights set on building up the very best in the industry
The R&D programme is intended to address the increasing prevalence of obesity and diabetes using smart siRNA
October 30 2018
The health sciences company noted that the plan was formulated at a recently held two-day intensive workshop which together leading scientific teams from the QIMR Berghofer Medical Research Institute in Brisbane and Murdoch University in Perth

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use